ERBB2 and non-small cell lung carcinoma: The most commonly described HER2 mutations in NSCLC are in-frame insertions in exon 20, which can act as proliferative drivers through constitutive activation of the receptor and downstream induction of PI3K/Akt and MEK oncogenic pathways [33].